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Background: Acute lower respiratory tract infection (LRTI) is one of the most common conditions managed
internationally and is costly to health services and patients. Despite good evidence that antibiotics are not effective for
improving the symptoms of uncomplicated LRTI, they are widely prescribed, contributing to antimicrobial resistance.
Many of the symptoms observed in LRTI are mediated by inflammatory processes also observed in exacerbations of
asthma, for which there is strong evidence of corticosteroid effectiveness. The primary aim of the OSAC (Oral Steroids
for Acute Cough) Trial is to determine whether oral prednisolone (40 mg daily for 5 days) can reduce the duration of
moderately bad (or worse) cough and the severity of all its associated symptoms on days 2 to 4 post-randomisation
(day 1 is trial entry) by at least 20% in adults ≥18 years with acute LRTI presenting to primary care.
Methods/design: OSAC is a two-arm, multi-centre, placebo-controlled, randomised superiority trial. The target sample
size is 436 patients, which allows for a 20% dropout rate. Patients will be recruited from primary care sites (General
Practitioner surgeries) across England and followed up until symptom resolution. The two primary clinical outcomes
are the duration of moderately bad (or worse) cough, and the severity of all its associated symptoms on days 2 to 4
post-randomisation. Secondary outcomes include: antibiotic consumption; symptom burden; adverse events;
participant satisfaction with treatment and intention to consult for future similar illnesses. A parallel economic
evaluation will investigate the cost-effectiveness of the intervention.
Discussion: Results from the OSAC trial will increase knowledge regarding the clinical and cost-effectiveness of
corticosteroids for LRTI, and will establish the potential of a new treatment option that could substantially improve
patient health. We have chosen a relatively high ‘efficacy dose’ as this will enable us to decide on the potential for
further research into lower dose oral and/or inhaled corticosteroids. This trial will also contribute to a growing body
of research investigating the natural course of this very common illness, as well as the effects of steroids on the
undesirable inflammatory symptoms associated with infection.
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Trial registration: Current Controlled Trials ISRCTN57309858 (31 January 2013).
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controlled trial, Efficacy, Cost-effectivenessBackground
Epidemiology, costs and current management of lower
respiratory tract infection
Lower respiratory tract infection (LRTI), defined as an
acute cough with at least one of sputum, chest pain,
shortness of breath and/or wheeze [1], is one of the
most common conditions managed in primary care in
the UK and internationally [2]. Over 75% of patients
presenting to primary care for this condition are pre-
scribed antibiotics [3,4] and have a 20% likelihood of
re-consulting within the same illness episode [1]. Acute
cough is estimated to cost the UK National Health Ser-
vice (NHS) at least £20 million annually in prescription
costs and £170 million in consultation costs [5,6]. Pa-
tient costs have been shown to be in excess of £15 per
episode [7], and respiratory tract infection is one of the
most common reasons for work absenteeism [8].
Despite good evidence that antibiotics do not reduce
the duration or severity of LRTI symptoms [2,5,9], they
continue to be widely prescribed [2,5]. This is adding to
the significant rise in antimicrobial resistance [10], which
is an increasing and serious threat to public health
[11,12]. Novel therapeutic measures are urgently needed
[6], and so far evidence of efficacy for alternative treat-
ments has not been demonstrated [13].
Rationale for testing the effectiveness of corticosteroids
in lower respiratory tract infection
Symptoms of LRTI include cough, wheeze and shortness
of breath, which are similar to the symptoms of exacer-
bated asthma [14,15]. Evidence suggests that the worst
symptoms may last up to 1 week, while complete symp-
tom resolution may take 3 weeks or more [5]. Prolonged
symptoms are thought to be due to a transient bronchial
hyper-responsiveness [16,17] and experimental evidence
suggests similar changes to bronchial epithelium in people
with and without asthma during a respiratory tract infec-
tion. Both groups have been shown to have significant re-
ductions in Forced Expiratory Volume (FEV), as well as
airways inflammation [14].
Oral and inhaled corticosteroids are widely pre-
scribed for the treatment of acute and chronic asthma,
respectively, and work by exerting an array of anti-
inflammatory effects [18]. There is increasing interest
in the potential role of corticosteroids in modifying the
undesirable effects of infection-associated inflammation
[19]. Benefits have already been demonstrated forchildren with acute croup [20] and community-acquired
pneumonia (if also given β agonists) [21], adults hospita-
lised with community-acquired pneumonia [22], adults
with post-infectious persistent cough [23] and adults with
acute tonsillitis [24].
At the time of writing there have been no published
studies of oral corticosteroid therapy for acute cough
following respiratory tract infection [6]; however, a num-
ber of trials of inhaled corticosteroids have been con-
ducted, of which one [25] is relevant to the Oral
Steroids for Acute Cough (OSAC) trial. This tested the
effects of high-dose fluticasone, 1 mg twice daily,
(equivalent to 2 mg twice daily of beclometasone [26] or
8.5 mg of oral prednisolone [27]) for 2 weeks in non-
asthmatic adults presenting to Dutch primary care with
a cough (LRTI) lasting more than 2 weeks. The inhaled
corticosteroids were effective in reducing the mean
cough frequency score among non-smokers, but the
clinical importance of the reduced cough score is uncer-
tain and there was no economic evaluation.
We are aware of two other ongoing trials currently reg-
istered on the International Controlled Trials Register [28]
to investigate the value of corticosteroids for other in-
fectious illnesses in primary care: the TOAST (Treatment
Options without Antibiotics for Sore Throat) trial
(ISRCTN17435450); and the OSTRICH (Oral STeroids
for Resolution of otitis media with effusion In CHildren)
trial (ISRCTN49798431).
Research and anecdotal evidence suggests that European
clinicians have started prescribing corticosteroids for LRTI
(in the absence of chronic obstructive pulmonary disease
(COPD)) [29], even though there is limited evidence to
support their use for this condition.
Long-term steroid use is known to be associated
with an array of unwanted systemic side effects such
as adrenal suppression, impaired skin collagen synthe-
sis and metabolic disturbances [30,31]. However, in the
absence of specific contraindications [30,32], a short
(up to 1 week) course of high-dose corticosteroids is
considered to be safe and associated with few side
effects [32-34].
The rationale for testing the effectiveness of corticoste-
roids in LRTI can be summarised as follows: (i) there is
good evidence of oral steroid effectiveness for acute
asthma; (ii) the symptoms of LRTI overlap with those of
acute asthma; (iii) prednisolone (tablets at a dose of 40 mg
daily for 5 to 7 days) is the most commonly used oral
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evidence to suggest that a minimum dose of 20 mg
daily is required for non-asthmatic patients [35]; and
(v) it is important that the first trial of its kind uses an
adequate dose to detect any potential effects as a proof
of concept.
Rationale for the trial design
This double-blind randomised controlled trial will
provide high quality evidence to determine whether
steroids are effective in the symptomatic treatment
of acute LRTI, for which, to date, non-steroidal anti-
inflammatory drugs [13], antibiotics [9] and inhaled
corticosteroids [6] have been shown to be ineffective. A
double-blinded, maximum dose design has been chosen
since: (i) the primary outcomes are subjective (in that
cough severity is reported by the participant); and (ii)
treatment with this agent for this clinical problem is
novel, making a trial demonstrating effectiveness under
optimal conditions important.
‘Duration of moderately bad or worse cough’ and
‘mean severity of all LRTI symptoms on days 2 to 4
post-randomisation’ have been selected as the primary
outcomes for this trial, in order to test the hypothesis
that the anti-inflammatory effects of corticosteroids will
relieve both the duration and severity of the unwanted
bronchospasm and other inflammatory side-effects of in-
fection. In another study, participants reported symp-
toms between days 2 and 4 as being the worst problem
[2], which provides the rationale for the timing for the
second primary outcome in this trial.
We recognise the undesirability of further medi-
calisation of common and self-limiting infections in
primary care [36], and if this trial demonstrates a
clinically important treatment effect, we do not think
it will be appropriate to promote the routine use of
high-dose corticosteroids for acute LRTI (though we
recognise that the prescription of corticosteroids to
alleviate the most acute symptoms of chest infections
remains a clinical decision). Rather, we think the im-
plication will be that further trials of lower-dose oral
or inhaled corticosteroids should be conducted. If no
treatment effect is found, it is unlikely that further,
lower-dose steroid research would be warranted for
acute LRTI.
Research questions
Primary research question
Can the use of oral prednisolone reduce the duration of
moderately bad or worse cough and/or the severity of all
its associated symptoms on days 2 to 4 post-randomisation
by at least 20% when compared to placebo treatment in
adults 18 years and over presenting to primary care with
acute LRTI?Secondary research questions
We will also: 1) assess the effects on antibiotic con-
sumption; 2) estimate the cost-effectiveness from the
perspectives of the NHS, patients, and society; 3) com-
pare the burden, severity and duration of abnormal
peak flow and LRTI symptoms; 4) compare adverse
events including any new symptoms or worsening of
existing symptoms, re-consultations for a documented
deterioration in illness and serious adverse events; 5)
investigate if participants’ subjective or objective re-
sponse to oral steroids is associated with a clinical diag-
nosis of asthma or COPD; and 6) assess participants’
satisfaction with treatment and intention to consult for
future similar illnesses.
Methods/design
This study is a placebo-controlled, individually rando-
mised, superiority trial in UK general practice.
Eligibility
We wish to test the effects of corticosteroids in adults
presenting to primary care with acute LRTI, in whom
there is no evidence of pneumonia or other reason to re-
quire an immediate antibiotic or hospitalisation, and in
whom there is no reason to consider the use of oral
prednisolone 40 mg daily for 5 days unsafe. At the same
time, the relatively high dose used in this trial requires
stringent exclusion criteria to ensure patient safety. The
eligibility criteria are as follows:
Inclusion criteria
The following inclusion criteria must all apply:
1. Aged 18 years or over;
2. Consulting for an acute (≤28 days) cough as the
main presenting symptom;
3. In the past 24 hours, the patient has had at least one
of the screening symptoms listed below (a-d),
localising to the lower respiratory tract and
suggestive of an acute LRTI:
a. phlegm (sputum)
b. chest pain
c. shortness of breath
d. wheeze
4. Patient and practice have sufficient time for consent
and randomisation into the trial by the end of the
day of consultation, or the next working day as long
as this is within 24 hours;
5. Patient able and willing to give informed consent
themselves;
6. Patient able and willing to complete the daily
symptom diary themselves;
7. Patient able, willing and available to receive weekly
telephone calls from the trial team.
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The presence of any of the following exclusion criteria
warrants exclusion:
1. Known lung cancer or chronic lung disease (for
example, cystic fibrosis, COPD, bronchiectasis);
2. Has an ‘active’ diagnosis of asthma (for which any
treatment has been given in the past 5 years);
3. The patient’s LRTI warrants same day hospital
admission or immediate antibiotics (note: use of
delayed prescription (post-dated by at least one
working day after the randomisation date) does not
preclude OSAC trial participation):
According to NICE guidelines, the patient warrants
immediate antibiotic treatment by virtue of one or
more of the following:
A. Is clinically very unwell or has symptoms and
signs suggestive of pneumonia, for example
tachypnoea (>20 bpm), unilateral chest signs or
consolidation, or hypoxia (oxygen saturation
<94%) or other systemic infection, for example
suspected bacteraemia
or
B. Is at high risk of complications, including
patients with chronic heart, chronic lung (for
example, COPD, bronchiectasis and cystic
fibrosis), chronic renal, chronic liver or
neuromuscular disease or immunosuppression;
or with complications from previous episodes of
lower respiratory tract infection, for example
hospital admission for pneumonia
or
C. Aged over 65 years with at least two of the
following criteria, or aged over 80 years with at
least one of the following criteria:
I. Unplanned hospitalisation within the previous
year
II. Type 1 or Type 2 diabetes
III.History of cardiac failure
4. Requires an oral or systemic antibiotic on the day of
consultation to treat another infection unrelated to
their acute cough, for example a co-existing
cellulitis (note: use of topical antibiotics does not
preclude OSAC trial participation);
5. Recently (≤1 month) used inhaled corticosteroids;
6. Recently (≤1 month) used short- (up to 2 weeks)
course systemic corticosteroids;
7. Currently using, or has previously (≤12 months)
used systemic steroids for a cumulative period
greater than 2 weeks, that is “long-term” use;
8. Known to be pregnant, is trying to conceive or is at
risk of pregnancy (for example, unwilling to take a
reliable form of contraception) in the next month;
9. Currently breast-feeding;10. This is not the patient’s usual practice, that is the
patient is visiting or is not intending to stay with the
practice for the 3 month trial follow-up period;
11. Previously randomised into the OSAC trial;
12. Has been involved in another medicinal trial within
the last 90 days or any other clinical research study
within the last 30 days;
13. Is unable to give informed consent or complete the
trial paperwork (including the symptom diary)
through mental incapacity, for example major current
psychiatric illness, learning difficulties and dementia;
14. Known immune-deficiency, for example chemotherapy
causing immunosuppression, asplenia or splenic
dysfunction, advanced cancer or HIV infection;
15. Patient due to receive the shingles vaccine in
conjunction with the influenza vaccine;
16. Has any of the following (A-P) known
contraindications or cautions to oral steroids:
Current or previous history of:
A. Peptic ulcer disease
B. Previous tuberculosis (TB)
C. No previous chickenpox and known recent
(≤28 days) history of close personal contact
with chickenpox or herpes zoster
D. Known allergy to prednisolone or other OSAC
trial tablet ingredients (potato starch, lactose
monohydrate, colloidal silicon dioxide, sodium
starch glycolate, magnesium stearate), galactose
intolerance, Lapp lactase deficiency or glucose-
galactose malabsorption
E. Osteoporosis
F. Glaucoma
G. Suspected ocular herpes simplex
H. Cushing’s disease
I. Epilepsy
J. Severe affective disorders, for example manic
depression, previous steroid psychosis
K. Previous steroid myopathy
L. Intention to use a live vaccine in the next
8 weeks or has received a live vaccine in the
previous 2 weeks (note: assess live vaccine
status by cross-checking with the British
National Formulary)
Current history only:
M.Uncontrolled diabetes (glycated haemoglobin or
HbA1C >8%)
N. Uncontrolled hypertension (note: as per
Responsible Clinician’s routine clinical judgement)
O. Taking other interacting medication
(e.g. phenytoin and anti-coagulants)
P. Any other British National Formulary listed
contraindication or caution (note: as per
Responsible Clinician’s routine clinical judgement)
17. Is unable to swallow tablets
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alisable patient population, recruitment will take place
across four collaborating UK trial centres: the Univer-
sities of Bristol, Nottingham, Oxford and Southampton.Intervention and blinding
Participants will be randomly assigned to one of two
treatments: (i) 2 × 20 mg oral prednisolone tablets daily
for 5 days or (ii) 2 × 20 mg oral placebo tablets daily for
5 days. Participants may stop taking the trial medication
before the 5 days if they feel completely better for two
consecutive days. Participants, clinicians and the trial
team (including the statisticians) will all be blinded to al-
location. All participants randomised to the trial will
continue to receive usual clinical care.Treatment allocation, concealment and emergency
unblinding
The computer-generated randomisation schedule will be
produced by a statistician who is independent of the
OSAC trial statisticians, and stratified by centre using a
variable block size. The schedule will be held by the
Pharmacy of the University Hospitals Bristol NHS Foun-
dation Trust (“the Pharmacy”), who will allocate medi-
cine packs containing active and placebo tablets and
identified by a unique Medicine ID number, to identical,
sequentially numbered Patient Packs identified by a
unique Participant ID number, which will then be sealed.
Packs, which are indistinguishable between active and
placebo groups, are issued sequentially to eligible, con-
sented patients at recruiting primary care sites. Clini-
cians, patients and all members of the research team
were masked to the randomisation sequence, and all
outcome data were gathered masked to allocation status.
The use of distinct Participant ID and Medicine ID
numbers will enable flexibility in the number of patients
recruited at each of the four trial centres. Medicine
packs can be combined with patient packs as needed,
allowing for temporary differential fluctuations in re-
cruitment rates between centres. The four centres will
be provided with Patient Packs to distribute to the par-
ticipating primary care sites in blocks of four (although
larger numbers of packs will be issued to practices with
proven capacity to recruit to this trial).
The Pharmacy will hold the master drug allocation log
and provide a 24 hour emergency unblinding service
based on a standard operating procedure for breaking the
code in the event of a medical emergency. Trial partici-
pants will be given a Trial Participation Card with details
of who their Responsible Clinician should contact in the
event of an emergency, and all practice-based clinicians
will receive training in the use of the emergency unblind-
ing service.At the end of the trial, the code-break will only be re-
leased to the investigative team once written confirm-
ation has been received that primary outcome data
analysis is complete.
Outcomes
How the outcome measures will be ascertained
The OSAC trial will use validated patient completed
symptom diary methods [37] that have been used in a
number of similar previous trials [2,5]. Participants will
record in the diary the severity of the following symp-
toms: cough; phlegm; shortness of breath; sleep disturb-
ance; feeling generally unwell; activity disturbance. A
symptom score scale of 0 to 6 will be used (0 = no prob-
lem, 1 = very little problem, 2 = slight problem, 3 =mod-
erately bad, 4 = bad, 5 = very bad, and 6 = as bad as it
could be) which is shown to be sensitive to change and
internally reliable [5]. For this trial, we will record all the
above symptoms for up to 28 days (or until symptom
resolution for two consecutive days) since LRTI duration
has been previously shown to last 3 to 4 weeks [5].
Cough duration and severity will be measured for up to
8 weeks since effects on these may not be apparent for
some time after using corticosteroids.
For this trial, participants will also record their peak
expiratory flow in the morning and the evening for the
duration of their illness up to 28 days, and measure
their quality of life at weekly intervals (up to 4 weeks)
using the EQ-5D-5L validated questionnaire [38],
which has been shown to be moderately responsive in
participants with acute cough/LRTI, and is a suitable
measure for use in economic evaluation studies of this
illness [39].
Primary outcome measures
1. Duration of moderately bad or worse cough (using a
validated web/paper-based symptom diary containing
an item asking participants to rate their cough from 0
to 6 (as described in ‘How the outcome measures will
be ascertained’ above). Duration is calculated as the
number of days from randomisation to the last day
that the participant scored 3 or higher, where that last
day is followed by at least two consecutive days where
the score is less than 3;
2. Mean of all symptom severity scores on days 2 to 4
post randomisation, measured using the symptom
diary. Severity of symptoms is scored 0 to 6 as for
cough, detailed above. Symptoms include cough,
phlegm, shortness of breath, disturbed sleep, feeling
generally unwell, and interference with normal
activities/work. A mean score will be calculated
across these symptoms for each of days 2, 3 and 4
and then an overall mean calculated.
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1. Antibiotic consumption;
2. Duration of corticosteroid tablet use;
3. Total duration and severity of symptoms (cough;
phlegm; shortness of breath; wheeze; blocked/runny
nose; chest pain; fever; muscle aching; headache;
sleep disturbance; feeling generally unwell; activity
disturbance), until the severity of each is scored by
the participant as ‘1’ or ‘very little problem, and
abnormal peak flow (defined as a peak flow reading
that is not within the range of values that would be
expected according to a standard predictive
algorithm based on gender, height and weight);
4. Adverse events including re-consultation for a
documented illness deterioration;
5. Patient satisfaction with treatment and intention to
use the same treatment if it were to be available in
the future;
6. Clinical diagnosis of asthma, COPD, whooping
cough (pertussis), or lung cancer at 3 months;
7. Quality of life (using the EQ-5D-5L);
8. NHS treatment and investigation costs, out-of-
pocket patient and family costs, and the cost to
society of time off work.
Sample size calculation
Since the distributions of both primary outcome vari-
ables (the duration of moderately bad or worse cough
and the mean severity score of all its associated symp-
toms on days 2 to 4 post-randomisation) will be posi-
tively skewed, sample size calculations are based on the
log-normal distribution.
The mean (standard deviation (SD)) duration of bad
or moderately worse cough was taken from a previous
study examining the effectiveness of prescribed antibi-
otics for acute LRTI [5] and estimated as 5.8 (4.1) days.
The mean (SD) symptom severity score between days 2
and 4 taken from the same trial was estimated as 2.3
(1.1). Using standard formulae for the mean and stand-
ard deviation of a log-normal distribution, this corre-
sponds to 1.555 (SD 0.637) log days (or geometric mean
of 4.74 days) for the cough duration outcome and 0.73
(SD 0.454) on the log scale (or geometric mean of 2.08)
for the symptom severity outcome.
To account for testing multiple primary outcomes a
lower alpha was specified for the symptom severity out-
come to ensure that the overall alpha for the two pri-
mary outcomes remains close to 5%. Moderately bad or
worse cough has been shown to resolve within 7 days
for 50% of patients, 14 days for 75% and 4 weeks for
90% of patients [5]. Therefore, since duration of cough
lasts significantly longer than the period during which
severity of symptoms are measured (days 2 to 4) and iscapturing an element of the illness severity, duration of
moderately bad or worse cough might be viewed as the
slightly more clinically important outcome. For this rea-
son alpha remained at 5% for duration of cough and was
reduced to 0.1% for symptom severity.
Sample size was calculated based on a 20% reduction
in the duration of cough, corresponding to a geometric
mean in the active treatment group of 3.79 days (mean
1.333 log days). Allowing (conservatively) for 20% attri-
tion, 218 participants will need to be randomised per
arm to retain 174 at follow-up and achieve 90% power
with a two-sided alpha of 0.05. Hence a total sample size
of 436 is required.
For the symptom severity outcome, a final achieved
sample size of 174 participants in each arm will provide
89% power to detect a reduction in symptom severity
score between days 2 and 4 of 20%, corresponding to a
geometric mean of 1.66 units in the active group (mean
0.51 log units) with a two-sided alpha of 0.001.
The trial team will make all efforts to recruit the 436
participants. If recruitment is slower than anticipated,
recruitment will be extended until at least 163 have been
recruited to each arm (326 in total). Assuming 20% attri-
tion, this would provide the study with 80% power for
both primary outcomes. All attempts will be made to en-
sure that attrition remains below 20% but if this is not
feasible recruitment will be extended further if possible.Trial medicines
The Investigational Medicinal Product for this trial will be
Prednisolone 20 mg oral tablets (×10), procured from
GALEN Pharma GmbH (Kiel, Germany). Placebo tablets
will be manufactured by Piramal Healthcare Ltd (Morpeth
UK) to exactly match the prednisolone tablets in dimen-
sions, appearance and taste, to maintain allocation blinding.
A relatively high dose of corticosteroids has been se-
lected in order to maximise the probability of detecting
a treatment effect (that is, an ‘efficacy’ dose) such that a
negative result cannot be criticised for being due to an
inadequate dose. The patient’s weight and height will be
recorded in order to allow us to take account of dose
effects.Recruitment sites
A minimum of 60 GP practices will be recruited to take
part in the trial across the four trial centres, with a wide
geographical spread in both urban and rural areas across
the South West, Midlands and North West of England.
The number recruited will take account of anticipated
ready to recruit (open) to actually recruiting (active) ra-
tios. Participating practices are required to have recent
(within 5 years) Good Clinical Practice (GCP) training
for all practice staff who will be confirming patients’
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tients or entering clinical data onto the online database.
Research ethics and governance
Multi-centre approval was granted by the Central Bristol
Research Ethics Committee (Ref: 12/SW/0180) and by the
MHRA (EudraCT number: 2012-000851-1). The lead Re-
search and Development organisation was the Western
(now West of England) Clinical Research Network. The
following Clinical Commissioning Groups provided Re-
search and Development approval for OSAC trial recruit-
ment at primary care sites within their localities: Bristol
(lead Clinical Commissioning Group); Berkshire East;
Birmingham CrossCity; Blackburn with Darwen; Bracknell
and Ascot; Coventry and Rugby; Cumbria; Dorset; East
Lancashire; Fylde & Wyre; Gloucestershire; Hardwick;
Kernow; Lancashire North; Leicester City; Nene; North and
West Reading; North Derbyshire; North East Hampshire
and Farnham; North Hampshire; North Somerset; Northern,
Eastern and Western Devon; Nottingham City; Oxfordshire;
Portsmouth; Redditch and Bromsgrove; Sandwell and West
Birmingham; Somerset; South Devon and Torbay; South
Eastern Hampshire; South Warwickshire; Warwickshire
North; West Hampshire; Wiltshire; Wokingham.
Please see Additional file 1 (SPIRIT checklist) for a
summary of how the protocol meets the recommenda-
tions of the SPIRIT (Standard Protocol Items: Recom-
mendations for Interventional Trials) initiative.
Screening for eligibility (the routine consultation)
Patients presenting with cough will be approached by
the healthcare professional managing their clinical care
(‘Responsible Clinician’) or by another member of the
practice team responsible for patient identification (for
example, reception staff or the ‘Recruiting Clinician’),
given a short explanation of the trial, and invited to be
screened for eligibility. If the patient is willing, the clin-
ician will screen the patient for eligibility. This process
includes a detailed check of the inclusion/exclusion cri-
teria, and a routine clinical examination, of which the re-
sults and the clinician’s diagnosis will be recorded on the
case report form (CRF). The routine clinical manage-
ment of the patient will be completed as normal. This
may include giving the patient a discretionary delayed
antibiotic prescription (to be used if the patient’s con-
dition deteriorates after 48 hours or if failing to improve
after 7 days) and the discretionary use of a β-agonist (for
example, salbutamol). A requirement for immediate anti-
biotic treatment renders the patient ineligible.
Once the patient’s eligibility is confirmed, the trial pre-
scription will be authorised (by a GCP-trained GP) for
redemption (by the Recruiting Clinician, not the patient)
against a trial Patient Pack. The patient is then referred
to a further interview for full recruitment and trial entry.Trial entry (the recruitment interview)
The recruitment interview must take place on the same,
or next, day as the routine consultation. Same-day re-
cruitment will be more efficient for many patients who
may not wish to return to the GP practice again the fol-
lowing day. Same-day recruitment will also help ensure
that participants take the first dose of their trial medica-
tion prior to collecting any delayed antibiotic that may
have been prescribed for them by their GP, thereby en-
suring the validity of antibiotic consumption as one of
the secondary outcome measures. Some patients may
wish to start taking a treatment on the same day that
they visit the GP practice, and in the absence of a trial
treatment those patients may be more likely to take anti-
biotics obtained from a delayed prescription or visited
another healthcare provider while waiting for the next
day to enter the trial.
However, if the site or patient do not have time for
the recruitment interview on the same day, the patient
can be recruited on the following working day, if the
following conditions are met: the recruitment interview
is not deferred to the Monday following a weekend, to
reduce the possibility of recruiting patients whose clin-
ical condition has deteriorated significantly since the
eligibility assessment was performed; and any delayed
antibiotic prescription is post-dated by at least 24 hours
after the recruitment interview, to ensure that the pa-
tient has the opportunity to take the first dose of their
trial medication prior to collecting their delayed anti-
biotic prescription.
The Recruiting Clinician will take formal written con-
sent, collect the remaining CRF data (including symp-
toms, signs and respiratory history), issue the patient
with the trial medicines and explain how to take them.
The patient will also receive a symptom diary, peak flow
meter and other materials to fully equip them for the
follow-up, and training in how to measure peak expira-
tory flow and complete the diary.
Participant follow-up
All follow-up will be managed by the trial team, who will
give participants individual support throughout their
follow-up period. Participants will complete the symp-
tom diary online or on paper every day for up to 28 days
or until symptoms have been completely resolved for
two consecutive days (whichever is soonest). As well as
recording the severity of their symptoms, completing the
symptom diary includes recording peak flow measure-
ments and whether or not any antibiotics have been
taken. The patient will also record how many of the trial
tablets they took on days 1 to 5, and any adverse effects
during the first 7 days.
All participants will be telephoned within the first
2 days of trial entry, and then each week for 4 weeks to
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data they have recorded during the preceding week (to
safeguard against potential loss of data if paper diaries
are not returned to the trial centre or there are problems
with the post), and to collect the weekly data on re-
source use and quality of life measures. These methods
are similar to those successfully used (with <20% attri-
tion) in previous studies [2,5,40,41].
Should the patient’s cough persist beyond 28 days,
their permission will be sought to continue with the
weekly calls, up to a maximum of 56 days, in order to
establish the day on which the patient last scores their
cough as “moderately bad”, and the date on which their
cough is completely resolved. The 56 day cut-off point
has been chosen as a pragmatic cut-off point, in order to
establish the date of cough resolution for the majority of
participants while taking account of the participant’s re-
search burden, and of the trial resources. The patient
will not be asked to complete any further trial paper-
work after the initial 28 day period.
Participants will receive thank you vouchers worth £15
during their participation in the trial, as there is system-
atic review evidence that small monetary tokens increase
response rates [42].
A review of participants’ primary care notes will be
undertaken by the recruiting primary care site, to record
NHS contacts (and their causes), prescriptions, second-
ary care referrals and any clinical diagnoses of asthma,
COPD, whooping cough or lung cancer in the 3 months
post-randomisation. This data collection will take place
at least 4 months after randomisation to allow for sec-
ondary care contacts and test results to be evident in the
primary care notes.
See Figure 1 (study flow chart) for a visual representa-
tion of the pathway of the trial participant through the
trial (presentation, index consultation, baseline recruit-
ment interview, and follow-up).
Data management
Clinical data will be collected and managed using a se-
cure, web-based system (OpenClinica) which will be
developed, hosted and supported by the University of
Oxford and validated by the University of Bristol.
Patient confidentiality will be maintained at all stages
of data collection. Eligible, consented, randomised pa-
tients will be identified by the Participant ID number
and the Medicine ID number of the allocated Patient
Pack. Entry of data into the on-line database will be the
default method of data capture; however, paper-based
alternatives will be provided in order to accommodate
GPs’ individual preferences. Participants will also be
given the choice between online and paper data collec-
tion: the symptom diary will be made available online,
with the exception of the EQ-5D-5L which will becompleted by the patient on paper and also collected
by the Trial Research Nurse during the weekly tele-
phone calls.
Analysis
Descriptive analyses will examine the comparability of
the intervention and control group at baseline.
Analysis of primary outcomes
Analysis and reporting will be in line with CONSORT
guidelines [43]. The primary comparative analysis will be
conducted on an intention-to-treat (ITT) basis. For all
analyses effect estimates will be presented with 95% con-
fidence intervals and P values. For the primary analysis
missing data will be assumed to be missing at random
and excluded from the analysis.
Duration of cough is calculated as the number of days
from the index consultation to the last day that the pa-
tient scored 3 or higher, where that last day is followed
by at least two consecutive days with a score of less
than 3. Cox proportional hazards models (adjusting by
centre) will be employed to examine differences in time
to recovery from moderately bad to worse cough be-
tween the two groups. Individuals not recovered at
28 days post-randomisation will be censored at this
time point. The assumption of proportional hazards
will be checked using Schoenfeld residuals.
Multiple linear regression models (adjusting for centre)
will evaluate the effectiveness of steroids in terms of redu-
cing symptom severity (the mean score of six symptoms)
on days 2 to 4.
For both primary outcomes models will also adjust for
any covariates demonstrating imbalance between the
groups at baseline.
Factors associated with missing data (such as demo-
graphics and values of primary and important second-
ary outcome variables at baseline) will be explored and
sensitivity analyses conducted (including inverse prob-
ability weights or multiple imputation methods, de-
pending on whether outcome data is partially or fully
missing).
It is anticipated that not all participants will complete
the full course of tablets; hence, in further sensitivity
analysis a per-protocol analysis will be performed.
Analysis of secondary outcomes
The secondary outcomes listed above (see “Secondary
outcome measures”) will be analysed using appropriate
regression models and will adjust for the baseline meas-
ure of the outcome, where possible, and centre.
Subgroup analyses
The following potential effect modifiers will be examined
by formal tests of interaction: age, duration of illness (both
Figure 1 Study flow chart. A visual representation of the pathway of the trial participant through the trial (presentation, index consultation,
baseline recruitment interview, and follow-up). CRF, case report form; LRTI, lower respiratory tract infection.
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of wheeze on auscultation, antibiotic consumption, β-
agonist prescriptions, smoking status, history of hay fever,
allergic rhinitis, eczema, and diagnosis of asthma or
COPD at 3 months (all yes/no). The trial is not specifically
powered for these analyses; interaction tests will therefore
be performed as hypothesis-generating analyses and inter-
pretation will focus on 95% confidence intervals.
Economic analysis
The economic analysis will use patient level data on par-
ticipant resource use over the 28 day period between ran-
domisation and the final follow-up telephone call. This
will be compared with outcomes measured at the 28-day
follow-ups. The analysis will consider three perspectives:
(1) the health care provider and personal and social ser-
vices (NHS and PSS); (2) participants and their families,
(3) societal cost of lost productivity due to time off work.
The costs associated with the NHS and PSS perspective
will include: trial and prescription medication costs, and
the costs associated with primary and secondary care
consultations. Participant resource use will include travel
to consultations, expenditure on over-the-counter medi-
cations, cost of extra domestic help and childcare, pre-
scription payments, and loss of earnings. The impact on
society due to time off work will be captured by partici-
pants’ reports of their own and their families’ absenteeism.
We will use the data listed above to construct a cost-
consequences matrix comparing cost from the three per-
spectives with the full range of primary and secondary
outcomes. We will estimate incremental cost-effectiveness
ratios comparing the extra cost, from the NHS perspec-
tive, of treating participants in the intervention group,
with the extra benefit gained. Benefit will be described as
(i) reduced cough duration, defined as the percentage of
participants in each group with a duration at least 20%
lower than the mean duration of participants in the con-
trol group or (if 20% reduction in mean duration in the
control group is less than 1 day) the percentage of partici-
pants in each group whose duration is at least 1 day less
than the mean of those in the control group; and (ii)
quality-adjusted life year (QALY) gain (QALY estimates
will be based on responses to the EQ-5D-5 L).
Sensitivity analyses will be used to test the robustness
of the results against assumptions made and bootstrap-
ping will be used to estimate the level of uncertainty
around the estimates of cost per QALY.
Discussion
This paper describes a placebo-controlled, randomised
multi-centre superiority trial that will establish the clinical
and cost effectiveness of a commonly used treatment (cor-
ticosteroids) for an entirely novel indication and one of
the commonest clinical problems managed in primarycare: acute LRTI. The trial will recruit between 326 and
436 non-asthmatic adult patients presenting to primary
care with an acute cough of less than 28 days duration
and at least one other lower respiratory tract symptom or
physical examination finding. Eligible, consented patients
will be randomised to receive a 5-day course of either
the active treatment (2 × 20 mg prednisolone daily) or
matched placebo, and asked to complete a symptom
diary for at least 7 and up to 28 days, depending on the
duration of their illness. Participants will be telephoned
weekly for 4 weeks, or until their cough resolves, up to
a maximum of 8 weeks from recruitment.
Trial status
The OSAC trial completed recruitment on 27 October
2014.
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